Soluble CD44 secretion contributes to the acquisition of aggressive tumor phenotype in human colon cancer cells

Experimental and Molecular Pathology

Volumn 83, Issue 3, 2007, Pages 341-346

  Subramaniam, Venkateswaran ^a,b   Gardner, Helena ^a,b   Jothy, Serge ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Apoptosis; Colon cancer; Decoy receptor; Proliferation; Soluble CD44

Indexed keywords

COMPLEMENTARY DNA; HERMES ANTIGEN; HYALURONIC ACID; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESISTANCE; CELL ADHESION; CELL ASSAY; CELL CLONE; CELL LYSATE; CELL PROLIFERATION; CLONOGENIC ASSAY; COLON CANCER; CONTROLLED STUDY; EXON; GENE VECTOR; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; PHENOTYPE; PROTEIN DEGRADATION; SUPERNATANT; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD44; APOPTOSIS; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; HUMANS; HYALURONIC ACID; MICE; PHENOTYPE;

EID: 36049005292     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2007.08.007     Document Type: Article

References (40)

1. Ahrens T., Sleeman J.P., Schempp C.M., Howells N., Hofmann M., Ponta H., Herrlich P., and Simon J.C. Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid. Oncogene 20 (2001) 3399-3408
2. Bendardaf R., Algars A., Elzagheid A., Korkeila E., Ristamaki R., Lamlum H., Collan Y., Syrjanen K., and Pyrhonen S. Comparison of CD44 expression in primary tumours and metastases of colorectal cancer. Oncol. Rep. 16 (2006) 741-746
3. Cichy J., and Pure E. The liberation of CD44. J. Cell Biol. 161 (2003) 839-843
4. Cichy J., and Pure E. Cytokines regulate the affinity of soluble CD44 for hyaluronan. FEBS Lett. 556 (2004) 69-74
5. Cichy J., Kulig P., and Pure E. Regulation of the release and function of tumor cell-derived soluble CD44. Biochim. Biophys. Acta 1745 (2005) 59-64
6. Dontu G., Liu S., and Wicha M.S. Stem cells in mammary development and carcinogenesis: implications for prevention and treatment. Stem Cell Rev. 1 3 (2005) 207-213 (Review, 77 refs)
7. Gamet-Payrastre L., Li P., Lumeau S., Cassar G., Dupont M.A., Chevolleau S., Gasc N., Tulliez J., and Terce F. Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res. 60 (2000) 1426-1433
8. Gunthert U., Hofmann M., Rudy W., Reber S., Zoller M., Haussmann I., Matzku S., Wenzel A., Ponta H., and Herrlich P. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65 (1991) 13-24
9. Gunthert A.R., Strater J., von R.U., Henne C., Joos S., Koretz K., Moldenhauer G., Krammer P.H., and Moller P. Early detachment of colon carcinoma cells during CD95(APO-1/Fas)-mediated apoptosis. I. De-adhesion from hyaluronate by shedding of CD44. J. Cell Biol. 134 (1996) 1089-1096
10. Guo Y.J., Liu G., Wang X., Jin D., Wu M., Ma J., and Sy M.S. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res. 54 (1994) 422-426
11. Herrera-Gayol A., and Jothy S. Adhesion proteins in the biology of breast cancer: contribution of CD44. Exp. Mol. Pathol. 66 (1999) 149-156
12. Jin L., Hope K.J., Zhai Q., Smadja-Joffe F., and Dick J.E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 12 (2006) 1167-1174
13. Kainz C., Tempfer C., Winkler S., Sliutz G., Koelbl H., and Reinthaller A. Serum CD44 splice variants in cervical cancer patients. Cancer Lett. 90 (1995) 231-234
14. Kosaki R., Watanabe K., and Yamaguchi Y. Overproduction of hyaluronan by expression of the hyaluronan synthase Has2 enhances anchorage-independent growth and tumorigenicity. Cancer Res. 59 (1999) 1141-1145
15. Krause D.S., Lazarides K., von Andrian U.H., and Van Etten R.A. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat. Med. 12 (2006) 1175-1180
16. Lackner C., Moser R., Bauernhofer T., Wilders-Truschnig M., Samonigg H., Berghold A., and Zatloukal K. Soluble CD44 v5 and v6 in serum of patients with breast cancer. Correlation with expression of CD44 v5 and v6 variants in primary tumors and location of distant metastasis. Breast Cancer Res. Treat. 47 (1998) 29-40
17. Lakshman M., Subramaniam V., and Jothy S. CD44 negatively regulates apoptosis in murine colonic epithelium via the mitochondrial pathway. Exp. Mol. Pathol. 76 (2004) 196-204
18. Lakshman M., Subramaniam V., Rubenthiran U., and Jothy S. CD44 promotes resistance to apoptosis in human colon cancer cells. Exp. Mol. Pathol. 77 (2004) 18-25
19. Lakshman M., Subramaniam V., Wong S., and Jothy S. CD44 promotes resistance to apoptosis in murine colonic epithelium. J. Cell. Physiol. 203 (2005) 583-588
20. Lockhart M.S., Waldner C., Mongini C., Gravisaco M.J., Casanova S., Alvarez E., and Hajos S. Evaluation of soluble CD44 in patients with breast and colorectal carcinomas and non-Hodgkin's lymphoma. Oncol. Rep. 6 (1999) 1129-1133
21. Masson D., Denis M.G., Denis M., Blanchard D., Loirat M.J., Cassagnau E., and Lustenberger P. Soluble CD44: quantification and molecular repartition in plasma of patients with colorectal cancer. Br. J. Cancer 80 (1999) 1995-2000
22. Murai T., Miyazaki Y., Nishinakamura H., Sugahara K.N., Miyauchi T., Sako Y., Yanagida T., and Miyasaka M. Engagement of CD44 promotes Rac activation and CD44 cleavage during tumor cell migration. J. Biol. Chem. 279 (2004) 4541-4550
23. Nakamura H., Suenaga N., Taniwaki K., Matsuki H., Yonezawa K., Fujii M., Okada Y., and Seiki M. Constitutive and induced CD44 shedding by ADAM-like proteases and membrane-type 1 matrix metalloproteinase. Cancer Res. 64 (2004) 876-882
24. Niitsu N., and Iijima K. High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin's lymphoma. Leuk. Res. 26 (2002) 241-248
25. Okamoto I., Kawano Y., Tsuiki H., Sasaki J., Nakao M., Matsumoto M., Suga M., Ando M., Nakajima M., and Saya H. CD44 cleavage induced by a membrane-associated metalloprotease plays a critical role in tumor cell migration. Oncogene 18 (1999) 1435-1446
26. Okamoto I., Kawano Y., Murakami D., Sasayama T., Araki N., Miki T., Wong A.J., and Saya H. Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. J. Cell Biol. 155 (2001) 755-762
27. Okamoto I., Tsuiki H., Kenyon L.C., Godwin A.K., Emlet D.R., Holgado-Madruga M., Lanham I.S., Joynes C.J., Vo K.T., Guha A., Matsumoto M., Ushio Y., Saya H., and Wong A.J. Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am. J. Pathol. 160 (2002) 441-447
28. Peterson R.M., Yu Q., Stamenkovic I., and Toole B.P. Perturbation of hyaluronan interactions by soluble CD44 inhibits growth of murine mammary carcinoma cells in ascites. Am. J. Pathol. 156 6 (2000) 2159-2167
29. Phillips T.M., McBride W.H., and Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation [see comment]. J. Natl. Cancer Inst. 98 24 (2006) 1777-1785
30. Ponta H., Sherman L., and Herrlich P.A. CD44: from adhesion molecules to signalling regulators. Nat. Rev., Mol. Cell Biol. 4 (2003) 33-45
31. Screaton G.R., Bell M.V., Jackson D.G., Cornelis F.B., Gerth U., and Bell J.I. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 12160-12164
32. Shipitsin M., Campbell L.L., Argani P., Weremowicz S., Bloushtain-Qimron N., Yao J., Nikolskaya T., Serebryiskaya T., Beroukhim R., Hu M., Halushka M.K., Sukumar S., Parker L.M., Anderson K.S., Harris L.N., Garber J.E., Richardson A.L., Schnitt S.J., Nikolsky Y., Gelman R.S., and Polyak K. Molecular definition of breast tumor heterogeneity. Cancer Cells 11 (2007) 259-273
33. Shirasawa S., Furuse M., Yokoyama N., and Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260 (1993) 85-88
34. Stickeler E., Vogl F.D., Denkinger T., Mobus V.J., Kreienberg R., and Runnebaum I.B. Soluble CD44 splice variants and pelvic lymph node metastasis in ovarian cancer patients. Int. J. Mol. Med. 6 (2000) 595-601
35. Subramaniam V., Li H., Wong M., Kitching R., Attisano L., Wrana J., Zubovits J., Burger A.M., and Seth A. The RING-H2 protein RNF11 is overexpressed in breast cancer and is a target of Smurf2 E3 ligase. Br. J. Cancer 89 (2003) 1538-1544
36. Subramaniam V., Vincent I.R., and Jothy S. Upregulation and dephosphorylation of cofilin: modulation by CD44 variant isoform in human colon cancer cells. Exp. Mol. Pathol. 79 (2005) 187-193
37. Sy M.S., Guo Y.J., and Stamenkovic I. Inhibition of tumor growth in vivo with a soluble CD44-immunoglobulin fusion protein. J. Exp. Med. 176 (1992) 623-627
38. Thorne R.F., Legg J.W., and Isacke C.M. The role of the CD44 transmembrane and cytoplasmic domains in co-ordinating adhesive and signalling events. J. Cell Sci. 117 (2004) 373-380
39. Wong K., Rubenthiran U., and Jothy S. Motility of colon cancer cells: modulation by CD44 isoform expression. Exp. Mol. Pathol. 75 (2003) 124-130
40. Yu Q., Toole B.P., and Stamenkovic I. Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J. Exp. Med. 186 12 (1997) 1985-1996